Iron chelators as therapeutic agents for the treatment of cancer.
about
The molecular effect of metastasis suppressors on Src signaling and tumorigenesis: new therapeutic targetsDrug development against metastasis-related genes and their pathways: A rationale for cancer therapySynthesis, Physicochemical Studies, Molecular Dynamics Simulations, and Metal-Ion-Dependent Antiproliferative and Antiangiogenic Properties of Cone ICL670-Substituted Calix[4]arenesAntiproliferative effect on HepaRG cell cultures of new calix[4]arenes. Part II.Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693.Transferrin receptor 2 is frequently and highly expressed in glioblastomasA multifunctional cytoprotective agent that reduces neurodegeneration after ischemia.Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?A systems biology approach to iron metabolism.In Vitro Antileukemic Activity of Xanthosoma sagittifolium (Taioba) Leaf Extract.Pro-Oxidant Activity of Amine-Pyridine-Based Iron Complexes Efficiently Kills Cancer and Cancer Stem-Like CellsEffect of microbial siderophores on mammalian non-malignant and malignant cell lines.Targeting cancer by binding iron: Dissecting cellular signaling pathwaysDeferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.Iron homeostasis regulates the activity of the microRNA pathway through poly(C)-binding protein 2.Is resistance useless? Multidrug resistance and collateral sensitivity.Reactions of N-benzyloxycarbamate derivatives with stabilized carbon nucleophiles: a new synthetic approach to polyhydroxamic acids and other hydroxamate-containing mixed ligand systemsHLA-G regulators in cancer medicine: an outline of key requirements.Molecular docking, PASS analysis, bioactivity score prediction, synthesis, characterization and biological activity evaluation of a functionalized 2-butanone thiosemicarbazone ligand and its complexes.Synthesis, molecular modeling, and biological evaluation of novel chiral thiosemicarbazone derivatives as potent anticancer agents.Structure-activity studies of 4-phenyl-substituted 2'-benzoylpyridine thiosemicarbazones with potent and selective anti-tumour activity.Antiproliferative effect on HepaRG cell cultures of new calix[4]arenes.Iron down-regulates macrophage anti-tumour activity by blocking nitric oxide production.Evaluation of the mobile phone electromagnetic radiation on serum iron parameters in rats.Alterations in the basal ganglia in patients with brain tumours may be due to excessive iron deposition.Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis.In vitro antiproliferative study of novel adamantyl pyridin-4-ones.The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.Complexing Behaviour and Antifungal Activity of N-[(1E)-1-(1H-Benzimidazol-2-yl)ethylidene]morpholine-4-carbothiohydrazide and Related Ligand with Metal Ions
P2860
Q26782593-CB7980EB-B125-48BF-BEC7-B4033C8439E0Q29010479-E55D9144-28F9-485D-A000-047B6EB1E727Q30615373-B2C72001-4D72-4336-B353-AA17266415FAQ33603341-A45C30C9-0819-4E61-954D-3E436BDF02AEQ33626022-3A28AFF9-DDC5-4106-B511-2207FCD343ABQ33760612-69F4B135-6567-4147-9195-D78A59ED4A39Q34335109-38F2B6DF-D804-413B-A2BB-A71FAAF7FCFDQ35056066-24BF9143-557F-4C45-ABD2-43669EE060A5Q35731204-32090268-9865-4023-AD1F-BC682D4BA0B8Q35768770-8FEBDE92-871E-4A22-A818-4610AE0E5911Q35773665-E9E10DF4-0D08-4C30-AD9B-BBFDA7021BD2Q36301248-934C892E-3626-424D-82E3-A951D663BA21Q36326247-DFBDC672-76F2-42A7-B98E-398656E3B7E7Q36681744-334A141E-A488-4D34-9E5F-5E2CCAB5631CQ36733696-6566A8DD-5B87-48FD-B026-F9E64635DC20Q37414081-E16AFC80-C106-4461-A2A9-125EF3E177BEQ37446333-D16F4B17-C18F-487E-B22D-2F4610FE32E7Q37906387-728151CE-0603-4D51-B431-578A76F40ED4Q38697900-0D24C15D-1C71-48F2-B5BA-22B703A8B1DAQ38940208-783AE7E5-1054-4FDF-AF2A-99A58B256F3AQ39107491-1A3B16FC-32E7-4DE1-97B9-DD483D5FBF35Q39780371-E05789C6-DEE9-4FB7-A663-6181EA6E38C8Q40545617-B3D89129-2DF3-4626-A4F9-575E9D195270Q42244807-BF205CB5-2E70-426A-8A9A-DDB281236DA6Q42469086-9057346E-7F02-47F3-A6FE-33B407593F51Q43241094-DE3BF5C0-6307-44C3-8AC1-6E21B52DDA74Q48147543-2554F4A5-434C-4F20-9F14-C25FB09C8B36Q53216728-881DEAE9-27C4-428F-BD6B-160101E270D4Q59043987-A726BAD6-ED41-4A9E-811E-4AC576D416D0
P2860
Iron chelators as therapeutic agents for the treatment of cancer.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Iron chelators as therapeutic agents for the treatment of cancer.
@ast
Iron chelators as therapeutic agents for the treatment of cancer.
@en
Iron chelators as therapeutic agents for the treatment of cancer.
@nl
type
label
Iron chelators as therapeutic agents for the treatment of cancer.
@ast
Iron chelators as therapeutic agents for the treatment of cancer.
@en
Iron chelators as therapeutic agents for the treatment of cancer.
@nl
prefLabel
Iron chelators as therapeutic agents for the treatment of cancer.
@ast
Iron chelators as therapeutic agents for the treatment of cancer.
@en
Iron chelators as therapeutic agents for the treatment of cancer.
@nl
P1476
Iron chelators as therapeutic agents for the treatment of cancer
@en
P2093
Richardson DR
P304
P356
10.1016/S1040-8428(01)00218-9
P577
2002-06-01T00:00:00Z